Zeremski Marija, Markatou Marianthi, Brown Queenie B, Dorante Gary, Cunningham-Rundles Susanna, Talal Andrew H
Division of Gastroenterology and Hepatology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA.
J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):262-8. doi: 10.1097/QAI.0b013e3180559219.
Elevated pretreatment interferon (IFN) gamma-inducible protein 10 (IP-10/CXCL10) levels are a marker of treatment nonresponse in hepatitis C virus (HCV)-monoinfected patients. We undertook this study to determine if IP-10 is a marker of treatment outcome in HCV/HIV-coinfected patients.
Nineteen HCV/HIV-coinfected patients were treated with weight-based pegylated (PEG) IFNalpha-2b (1.5 microg/kg) once weekly plus weight-based ribavirin (1000 or 1200 mg) daily for up to 48 weeks. Plasma IP-10, monokine induced by IFNgamma/CXCL9 (Mig), and IFN-inducible T-cell alpha-chemoattractant/CXCL11 (I-TAC) levels were measured by enzyme-linked immunosorbent assay on samples obtained frequently during the first 3 PEG-IFN doses and throughout treatment.
Median pretreatment plasma IP-10 (interquartile range [IQR]) levels were significantly lower in virological responders (n=6) at 217 (IQR: 181-301) pg/mL compared with nonresponders (n=13) at 900 (IQR: 628-2048) pg/mL (P=0.002), whereas pretreatment Mig and I-TAC levels did not differ significantly. Plasma IP-10 levels of 400 pg/mL before treatment and on days 7 and 14 could be used to identify likely coinfected PEG-IFN/ribavirin nonresponders. PEG-IFN-induced elevations in IP-10 were greater in virological responders than in nonresponders (approximately 10-fold vs. approximately 4-fold) after the first PEG-IFN dose.
IP-10 may be a biomarker of HCV treatment outcome in difficult-to-treat HCV/HIV-coinfected patients.
在丙型肝炎病毒（HCV）单感染患者中，治疗前干扰素（IFN）γ诱导蛋白10（IP-10/CXCL10）水平升高是治疗无应答的一个标志物。我们开展本研究以确定IP-10是否为HCV/ HIV合并感染患者治疗结局的一个标志物。
19例HCV/ HIV合并感染患者接受基于体重的聚乙二醇化（PEG）干扰素α-2b（1.5μg/kg）每周1次加基于体重的利巴韦林（1000或1200mg）每日1次治疗，疗程长达48周。通过酶联免疫吸附测定法检测在前3剂PEG-IFN期间及整个治疗过程中频繁采集的样本中的血浆IP-10、IFNγ诱导的单核因子/CXCL9（Mig）和IFN诱导的T细胞α趋化因子/CXCL11（I-TAC）水平。
病毒学应答者（n = 6）治疗前血浆IP-10水平中位数（四分位间距[IQR]）为217（IQR：181 - 301）pg/mL ,显著低于无应答者（n = 13）的900（IQR：628 - 2048）pg/mL（P = 0.002），而治疗前Mig和I-TAC水平无显著差异。治疗前以及第7天和第14天血浆IP-10水平为400 pg/mL可用于识别可能的合并感染的PEG-IFN/利巴韦林无应答者。首次给予PEG-IFN后，病毒学应答者中PEG-IFN诱导的IP-10升高幅度大于无应答者（约10倍对约4倍）。
IP-10可能是难以治疗的HCV/ HIV合并感染患者HCV治疗结局生物标志物。
